AzTrials
AzTrials

Advanced Solid TumorsPhase 1NCT01210846

A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors

A Phase 1 study testing tivozanib in people with Advanced Solid Tumors, run by AVEO Pharmaceuticals, Inc. at 8 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to obtain QTc data, to assess the effects of tivozanib on ECG morphology, and to determine the pharmacokinetic pharmacodynamic (PK-PD) relationship between any observed changes in cardiac repolarization (defined by QTcF duration) and the serum concentration of tivozanib. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Advanced Solid Tumors
What is being tested?
tivozanib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
8 sitesUnited States
Study dates
Oct 2010to Jul 2011
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Males or females, ≥18 years of age;
  • Diagnosis of an advanced solid tumor malignancy with histological or cytological evidence;
  • Advanced malignancy, metastatic or unresectable, that has recurred or progressed following standard therapy or failed standard therapy; or for which no standard therapy currently exists; or for which subject is not a candidate, or is unwilling to undergo standard therapy;
  • Tumor is not currently amenable to curative surgical intervention;
  • Recovery from the effects of any prior surgery, radiotherapy, or systemic antineoplastic therapy;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and life expectancy ≥ 3 months;
  • Well controlled thyroid function, in the opinion of the Investigator;
  • Able to comprehend and willing to sign an Informed Consent Form (ICF) and able to adhere to dose and visit schedule.

Who cannot join

  • Women who are breast-feeding, pregnant, or intend to become pregnant;
  • Primary central nervous system (CNS) malignancies or CNS metastases; subjects with previously treated brain metastasis will be allowed if the brain metastasis have been stable without steroid treatment for at least 3 months following prior treatment (radiotherapy or surgery);
  • Clinically significant cardiac disease (New York Heart Association class > 2) including unstable angina, acute myocardial infarction within 6 months of Day 1, congestive heart failure, or arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities, per Investigator judgment;
  • Uncontrolled hypertension: systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg on 2 or more antihypertensive medications, documented on 2 consecutive measurements taken at least 24 hours apart;
  • Baseline ECG, QTcF > 480 ms. If the screening QTcF is > 480 ms, this may be repeated once and if the QTcF is ≤ 480 ms the subject can be enrolled;
  • Any of the following hematologic abnormalities:
Show all 51Show fewer
  • hemoglobin < 9.0 g/dL;
  • Absolute neutrophil count < 1500 per mm3;
  • platelet count < 100,000 per mm3;
  • INR > 1.5 x upper limit of normal (ULN);
  • Any of the following serum chemistry or urine abnormalities:
  • total bilirubin > 1.5 × ULN (or > 2.5 × ULN for subjects with Gilbert's syndrome);
  • AST or ALT > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis);
  • alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone metastasis);
  • creatinine > 2.0 × ULN;
  • proteinuria > 3+ by urinalysis;
  • Non healing wound, bone fracture, or skin ulcer;
  • Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug;
  • Serious/active infection or infection requiring parenteral antibiotics or antifungal therapy;
  • Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug;
  • Significant thromboembolic or vascular disorders or surgery within 6 months prior to administration of first dose of study drug, including but not limited to:
  • deep vein thrombosis;
  • pulmonary embolism;
  • cerebrovascular accident or transient ischemic attack;
  • peripheral arterial ischemia > Grade 2;
  • coronary or peripheral artery bypass graft;
  • Significant bleeding disorders within 6 months prior to administration of first dose of study drug, including but not limited to:
  • hematemesis, hematochezia, melena or other gastrointestinal bleeding ≥ Grade 2;
  • hemoptysis or other pulmonary bleeding ≥ Grade 2;
  • hematuria or other genitourinary bleeding ≥ Grade 2;
  • Currently active second primary malignancy, including hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc), other than non melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer and ductal or lobular carcinoma in situ of the breast. Subjects are not considered to have a currently active malignancy if they have completed anti-cancer therapy and have been disease free for >2 years;
  • History of genetic or acquired immune suppression disease such as human immunodeficiency virus (HIV), subjects on immune suppressive therapy for organ transplant;
  • Life-threatening illness or organ system dysfunction compromising safety evaluation;
  • Inability to swallow pills, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of tivozanib, major resection of the stomach or small bowel, or gastric bypass procedure;
  • Psychiatric disorder or altered mental status precluding informed consent or necessary testing;
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator;
  • Use of Seville orange- or grapefruit-containing foods or beverages within 72 hours prior to Day 1;
  • Poor venous access;
  • Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study;
  • Sexually active male and pre-menopausal female subjects (and their partners) unless they agree to use adequate contraceptive measures, while on study and for 30 days after the last dose of study drug. All fertile male and female subjects (and their partners) must agree to use a highly effective method of contraception. Highly effective birth control includes (a) IUD plus one barrier method; or (b) two barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.
  • Drugs and Other Treatments to be Excluded
  • Prohibited 4 weeks prior to first dose and for the duration of the study:
  • Chemotherapy, biological therapy (including cytokines, signal transduction inhibitors, monoclonal antibodies), immunotherapy, experimental therapy or any other therapy for treatment of advanced solid tumors;
  • Systemic hormonal therapy, with the exception of: i. hormonal therapy for appetite stimulation or contraception; ii. nasal, ophthalmic, inhaled and topical steroid preparations; iii. androgen suppression therapy for non-metastatic prostate carcinoma; iv. hormone replacement therapy for conditions such as adrenal insufficiency, hypothyroidism, etc.; v. low-dose maintenance steroid therapy (equivalent of prednisone ≤ 10 mg/day) for other conditions;
  • Prohibited 3 weeks prior to first dose and for the duration of the study:
  • Treatment with radiotherapy (limited radiotherapy involving ≤ 25% of bone marrow may be allowed for palliative purposes after consultation with the medical monitor, treatment with study drug must be stopped during radiotherapy);
  • Prohibited 2 weeks prior to first dose and for the duration of the study:
  • Herbal preparations/supplements/topical applications (except for daily multivitamin/mineral supplement not containing herbal components);
  • Treatment with CYP3A4 inducers or inhibitors (see Appendix C for examples);
  • Prohibited 1 week prior to first dose and for the duration of the study:
  • Treatment with full dose oral anticoagulants such as warfarin, acenocoumarol, fenprocoumon, or similar agents. If previously receiving these types of agents, a minimum washout of 1 week and documented PT of < 1.5 × ULN will be required prior to start of therapy. Full dose anticoagulation with low molecular weight heparin or unfractionated heparin administered subcutaneously is allowed. Low dose oral anticoagulation (eg, 1-2 mg/day warfarin) is allowed provided PT remains < 1.5 × ULN during the study.

Trial locations and contacts

8 sites in 1 country.

8 sites in 1 country

United States8 sites

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Horizon Oncology Research, Inc.

    Lafayette, Indiana

  • Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC

    Metairie, Louisiana

  • Tennessee Onocology

    Nashville, Tennessee

  • Oklahoma University Cancer Institute (OUCI)

    Oklahoma City, Oklahoma

  • Associates in Oncology/Hematology

    Rockville, Maryland

  • TGEN Clinical Research Service at Scottsdale Healthcare

    Scottsdale, Arizona

  • Multicare Research Institute/Tacoma General Hospital

    Tacoma, Washington

Other trials in United States

About this study

Official title: An Open-Label Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors

The purpose of this study is to obtain QTc data, to assess the effects of tivozanib on ECG morphology, and to determine the pharmacokinetic pharmacodynamic (PK-PD) relationship between any observed changes in cardiac repolarization (defined by QTcF duration) and the serum concentration of tivozanib.

Read the detailed description

Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.

This study is an open-label, non-randomized, exploratory single-arm trial evaluating the ECG and pharmacokinetic (PK)-ECG relationship, if any, of tivozanib in subjects with advanced solid tumors.

The purpose of this study is to evaluate the ECG intervals and morphology following treatment with tivozanib in subjects with advanced solid tumors and to determine the relationship, if any, of the change in QTc duration with serum concentration of tivozanib over time in subjects with advanced solid tumors.

Being tested
tivozanib
Keywords
AV-951, tivozanib, QTc, advanced solid tumors, pharmacokinetics

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • tivozanibDrug

    1 x 1.5 mg capsule of tivozanib orally once daily for 21 days

Study groups in NCT01210846
Study groupRoleWhat they receive
tivozanibExperimentalNot described
Receives: Drug: tivozanib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline in QTcF

    Measured: 22 days

Secondary outcomes (7)

  1. Change from baseline in QTc with Bazett correction method (QTcB)

    Measured: 22 days

  2. Change from baseline in heart rate (HR)

    Measured: 22 days

  3. Change from baseline in PR interval

    Measured: 22 days

  4. Change from baseline in QRS interval

    Measured: 22 days

  5. Change from baseline in Uncorrected QT interval

    Measured: 22 days

  6. Change from baseline in ECG morphological patterns

    Measured: 22 days

  7. Correlation between the QTcF change from baseline and serum concentrations of tivozanib

    Measured: 22 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Sep 2010 (estimated)
  2. Study startOct 2010
  3. Primary completionMar 2011
  4. Study completionJul 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01210846
Sponsor's protocol ID
AV-951-10-112
Status last verified
Sep 2011
First submitted
27 Sep 2010
Last updated
26 Sep 2011
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing tivozanib in people with Advanced Solid Tumors, run by AVEO Pharmaceuticals, Inc. at 8 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 51 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Sep 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in QTcF (time frame: 22 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01210846.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2011.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in